Colorectal Cancer Alliance Sponsors

Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine. Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives.

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide.

Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, Boston Scientific advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life by providing the highest-quality biopharmaceutical products. They are focused on both finding innovative medicines to combat serious diseases and on getting them to patients faster and more efficiently.

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumors, emphysema, blood clots, and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.

The Boehringer Ingelheim group*, the makers of Dulcolax, is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

*Dulcolax® products are marketed and distributed by Boehringer Ingelheim Pharmaceuticals, Inc.

Epi proColon® is the First and Only FDA-approved blood test for colon cancer screening.  Epi proColon is intended for patients who can’t or won’t complete a colonoscopy or take-home stool test.  Available at national laboratory chains. www.crcbloodtest.com

Genentech BioOncology is an industry leader in researching the molecular basis of cancer with a long-standing commitment to fundamentally transforming the way cancer is treated. Genentech believes that studying the biological pathways involved in cancer development, progression and metastasis holds the key to identifying promising molecular targets. Genentech BioOncology is focused on both the basic biology of cancer and its application to therapeutics in oncology.

At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with rare cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class or best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.

For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Today, Lilly Oncology continues to place a priority on speeding innovation that will improve outcomes for individual patients facing cancer. And because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches

Myriad Genetics is dedicated to saving lives and improving the quality of life for patients worldwide through the discovery and commercialization of novel, transformative diagnostic products and services across major diseases.

Olympus is a global technology leader, crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products. Throughout our nearly 100-year history, Olympus has focused on being true to society and making people’s lives healthier, safer and more fulfilling every day. Visit www.olympusamerica.com.

Salix is committed to being the leading U.S. specialty pharmaceutical company licensing, developing and marketing innovative products to healthcare professionals to prevent or treat gastrointestinal disorders in patients while providing rewarding opportunities for our employees and creating exceptional value for our stockholders.

Taiho Oncology, Inc. works urgently to discover and develop innovative cancer treatments. As cancer evolves, we evolve with it—bringing novel technology to cornerstone chemotherapies, while at the same time optimizing new targeted agents. Advanced technology, dedicated investigators, and incomparable facilities—these vast resources empower us to redefine the way the world treats cancer.